knowledge -WSS

knowledge

author：hotspot 2025-09-30 16:28:32 - browse：43

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Covid's long

leisure time

WSS

Young boy dies in trial for Pfizer Duchenne gene therapy

Bird flu reported in person exposed to presumably infected cattle

Who are the detained American citizens released from prison in Iran?

Drug companies' payments and gifts affect physicians' prescribing

Gut bacteria may contribute to kidney autoimmunity, study finds

The history of OxyContin, told through Purdue Pharma documents

Wikipedia

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Bird flu in dairy cattle: New measures to control spread to humans

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

In Memoriam: Notable people who died in 2023

Study: Black kids more likely to die after surgery than white kids

How one medical school became remarkably diverse

CDC overhauls leadership of center that led response to Covid

Medicare details structure of new drug price negotiation program

Young boy dies in trial for Pfizer Duchenne gene therapy

focus

An innovative path out of biotech’s “valley of death”

Hundreds died while taking an arthritis drug, but nobody alerted patients

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Republican states more likely to report Covid vaccine side effects

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Insurer loopholes limit power of law against surprise medical bills

leisure time

explore

knowledge

entertainment